Levodopa methyl ester and benserazide mixed medicament slow-release microsphere composition and preparation method thereof

Abstract

The invention relates to a levodopa methyl ester and benserazide mixed medicament slow-release microsphere composition. The composition comprises the following components in percentage by weight: 50 to 99 percent of degradable hydrophobic polymer and 1 to 50 percent of levodopa methyl ester and benserazide mixed medicament, wherein the weight ratio of the levodopa methyl ester to the benserazide is 1:1-4:1. The invention also provides a preparation method for the mixed medicament slow-release microsphere composition. The invention overcomes the disadvantage of unavailable effective treatment due to frequent missing of administration caused by the conventional single oral administration scheme and frequent oral administration requirement and provides a W / O / W preparation method. The particle diameter of the composition can be regulated and controlled from 1 to 500mu m according to different requirements without causing environmental pollution; the composition can prevent the influence on the treatment effect of the levodopa methyl ester and benserazide mixed medicament; the solution has the advantages of smooth and round surface, regularity and no adhesion; and the freeze-dried powder of the composition is white, fine, loose, non-collapse and non-adhesive and has high dispersibility.

Description

A kind of levodopa methyl ester and benserazide mixed drug sustained-release microsphere composition and preparation method thereof 【Technical field】 The invention relates to a composition in the technical field of pharmaceutical preparations and a preparation method thereof, in particular to a drug sustained-release microsphere composition of mixed levodopa methyl ester and benserazide and a preparation method thereof. 【Background technique】 In the pharmaceutical industry, from drug discovery to clinical application, the last link is drug preparation. A considerable part of the drugs need long-term frequent administration to be cured; some of them need local administration due to the high toxicity of systemic administration. To achieve these goals, raw materials must be prepared into corresponding dosage forms. For example, drugs that require long-term administration but have a short half-life in the body should be prepared as sustained-release or controlled-release dosa...

AI Technical Summary

Problems solved by technology

However, there is currently no report on the preparation of levodopa methyl ester and benserazide mixed drug sustained-release microspheres, and a single levodopa methyl ester and benserazide mixed drug sustained-release microspheres are easily degraded by enzymes in the body and inactivated

Images